Inventory (Tables)

9 Months Ended

Sep. 30, 2025

Inventory Disclosure [Abstract]

Schedule of Inventory

The Company capitalizes its purchases of saleable inventory of VASCEPA from suppliers that have been qualified by the U.S. FDA and other global regulatory agencies. Inventories as of September 30, 2025 and December 31, 2024 consist of the following:

In thousands	September 30, 2025		December 31, 2024
Raw materials	$	96,154	$	91,421
Work in process		9,211		30,482
Finished goods		88,444		108,885
Total inventory 1	$	193,809	$	230,788

(1) Total inventory consists of both current inventory and long-term inventory. During the nine months ended September 30, 2025, approximately $0.4 million of inventory was expensed through cost of goods sold for product dating inventory. During the nine months ended September 30, 2024, approximately $1.5 million of inventory was expensed through cost of goods sold for product dating inventory.